NasdaqGS:APLSBiotechs
Apellis Pharmaceuticals (APLS) Is Up 9.8% After Strong SYFOVRE Demand Lifts Preliminary 2025 Revenues
Apellis Pharmaceuticals recently presented at the 44th Annual J.P. Morgan Healthcare Conference, where management highlighted preliminary 2025 U.S. net product revenues of about US$689 million, supported by a 17% year-over-year increase in demand for SYFOVRE and early traction for EMPAVELI in rare kidney conditions.
The company also outlined plans to advance a prefilled syringe version of SYFOVRE and expand EMPAVELI’s nephrology reach, while indicating that existing cash and product revenues...